Risk of Cardiovascular Death in the Remote Period after Myocardial Revascularization and in Association with Renal Dysfunction

E. Levitskaya, PhD¹*; M. Batiushin, PhD,ScD¹; A. Hripun, PhD¹; A. Kastanajan, PhD,ScD¹; E. Golovinova¹; V. Gul’chenko¹; D. Pasechnik, PhD¹; V. Chistyakov, PhD, ScD¹, ²; I. Dudarev, PhD, ScD; G. Shavkuta, PhD, ScD

¹Rostov State Medical University, ²Southern Federal University; Rostov-on-Don, Russia

*Corresponding author: Ekaterina S. Levitskaya, PhD. Rostov State Medical University, Rostov-on-Don, Russia.  E-mail: es.med@mail.ru

 Published: March 16, 2016. DOI: 10.21103/Article6(1)_OA2


The aim of the present study was to assess the effectiveness of standard medical therapy in lowering the risk of cardiovascular death (rCVD) in the remote period after myocardial revascularization (MR), taking into account the presence of renal dysfunction (RD).

Material and Methods: The study included 90 patients with coronary heart disease (CHD) and indications for revascularization. We evaluated a drug therapy obtained at different stages of revascularization, as well as the severity of patients’ condition and the prevalence of RD.

Results:  In the remote period after MR (5.8±0.05 years), 71/78.9% patients participated in the study; death occurred in 10/12.3% patients. The duration of therapy for chronic myocardial ischemia before MR (P=0.005), as well as compliance with prescribed therapy during 6 months (P=0.008) after this procedure, affected CVD in the remote period after MR. Using statins before MR reduced rCVD by 17.2% (P=0.01), beta-blockers -14.95% (P=0.04), and ACE inhibitors (ACEIs) - 15.75% (P=0.03). The lack of regular use of acetylsalicylic acid (ASA) for 6 months after RM was associated with an increase in rCVD up to 36.2% (P=0.005). Statins and ACEIs are drugs that reduce rCVD in the presence of RD (P<0.05).

Conclusion: An efficient drug regimen for patients after MR is important in reducing a long-term prognosis of CVD and for an efficient correction of coronary artery patency. 

risk of cardiovascular death; ischemic heart disease; revascularization; renal dysfunction.

1. World Health Organization. Global Status Report on Noncommunicable Diseases 2014. http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf

2. Castellano JM, Narula J, Castillo J, Fuster V. Promoting Cardiovascular Health Worldwide: Strategies, Challenges, and Opportunities. Rev Esp Cardiol (Engl Ed). 2014; 67(9): 724-30.

3.  Tuso P,  Stoll SR,  Li WW. A Plant-based diet, atherogenesis, and coronary artery disease prevention. Perm J. 2015; 19(1): 62-7.

4. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. Eur Heart J. 2014 Oct 1;35(37):2541-619.5.

5. Philip F,  Blackstone E,  Kapadia SR. Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery. Cardiovasc Diagn Ther. 2015; 5(1): 8-16.

6. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425-35.

7. Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation 2008; 118(18):1785-92.

8. Zhang H, Yuan X, Zhang H, Chen S, Zhao Y, Hua K,  et al. Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery. Circulation. 2015; 131(25):2194-201.

9. Levitskaya ES, Chesnikova AI, Batiushin MM, Terent'ev V.P. Assessing the impact of renal risk factors on the probability of recurrence of angina pectoris in patients undergoing myocardial revascularization, optimization of drug therapy. Arch Inter Med. 2012;(5):45-50. [In Russian].

10. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006; 98(1): 121-8.

11. Minuzzo L, Santos ES, Timerman A. Association between angiotensin-converting enzyme inhibitors and troponin in acute coronary syndrome. Arq Bras Cardiol. 2014; 103(6): 513-20.

12. Agarwal R. Effects of statins on renal function. Mayo Clin Proc. 2007; 82(11): 1381-90.

13. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3): 238-48.

14. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407.

15. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.  Lancet. 2011; 377(9784):2181-92.

16. Tan KS, Johnson DW. Managing the cardiovascular complications of chronic kidney disease. Aust Prescr 2008; 31: 154-8.

17. Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008; 3 Suppl 1:S3-10.

The fully formatted PDF version is available.

Download Article

Int J Biomed. 2016; 6(1):12-17. © 2016 International Medical Research and Development Corporation. All rights reserved.